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INTRODUCTION
• PARP inhibitors (PARPi) have been found to be 
most effective when targeting BRCA1 and 2 
breast and ovarian cancers.
• Defects in both these complementary DNA repair 
pathways underlie the principle of synthetic 
lethality, which is thought to be the reason for 
PARPi mediated killing of BRCA2 defective 
cancer cells. 
• If that were the case, PARPi should kill cells 
shortly after being administered (as DSBs would 
accumulate after every replication). However, 
PARPi-induced cell killing in vitro does not occur 
until several days after drug exposure, and the 
reason for this is unknown. 
• PARPi recently have been found to activate pro-
inflammatory cytokine production (i.e. TNFα), as 
does chronic inactivation of BRCA2. 
• We hypothesize that PARPi induced immune 
signaling (i.e. TNFα) contributes to the synthetic 
lethality with BRCA2.
METHODS
BRCA2 depleted BJ cells were seeded in multiple 
96-well plates and treated with differing 
concentrations of Olaparib (a PARPi). Two and three 
days later, the supernatant (SN) transfer of 
Olaparib-treated cells was transferred to untreated 
cells with and without BRCA2 depletion. To test the 
potential involvement of TNFa, an inhibitor of TNFα 
was included to treated and untreated cells. Cell 
survival was assessed using Zen Imaging software 
and MTS colorimetric survival assay 5 days after 
initial PARPi treatment. 
• Cell culture (BJ and VU432 cells)
• Supernatant transfer from treated to 
untreated cells
• Cell splitting, seeding/plating and drug 
treatment
• Cell harvesting for western blot
• MTS assay 
• Zeiss Microscopy Zen Imaging Software
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Fig. 1 DNA damage repair and synthetic lethality. Single 
strand breaks are repaired by PARP, so inhibiting it will 
lead to double strand breaks (DSBs). DSBs are repaired by 
BRCA2 (and BRCA1- not shown here), so if that is also 
defective         cell death























• We wanted to see if the SN of PARPi-treated 
cells- theoretically containing cytokines (i.e.
TNFα)- would also kill untreated cells as that 
would suggest inflammation signaling is the 
reason behind PARPi killing of BRCA2 depleted 
cells, as opposed to synthetic lethality by DNA 
repair defects. 
• If cells treated with SN died while those with SN + 
TNFαi didn’t, that would mean that TNFα is the 
main immune signaling factor that is involved with 
PARPi killing.
• As of now, we have no concrete evidence to 
support the hypothesis as our results aren’t 
statistically significant. Final experiment should be
repeated in case of human error.
RESULTS


























































































Fig. 2 Semi-log dose response curve of VU432 and BJ 
(wild-type) cells treated with Olaparib (0.3 to 100uM) . 
Used to select drug concentration for further experiments. 
Fig. 3 Supernatant (SN) transfer from treated  (Olaparib, 3uM) and
untreated BJ and VU432 to naive BJ and VU432 cells. Humira (a 
TNFαi) was added to half of the treated supernatant before 
administration to naive cells. Cell survival was assessed through MTS 
assay after 3 days. 
Fig. 4 Supernatant transfer from BJ cells with Luc (control) and 
BRCA2 knockdowns- treated with 1 and 3 uM Olaparib (1uM shown 
here)- to untreated BJ cells with Luc and BRCA2 knockdowns. 
Further details under ‘Methods.’
Since BJ cells, unlike VU432, 
are rescued upon addition of 
TNFαi, we decided to use them 
in the next step (Fig 4), for 
BRCA2 knockout
